Epcoritamab-bysp causes release of cytokines [see Clinical Pharmacology (12.2) ] that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates.
Source: FDA drug label - epcoritamab-bysp
Epcoritamab Interactions
1 interaction on record